title: Management of opportunistic infections complicating the acquired immunodeficiency syndrome.
abstract: Therapy of opportunistic infection in patients with the acquired immunodeficiency syndrome is frustrating, and there is no convincing evidence that aggressive treatment and/or prophylaxis other than for Pneumocystis infection can significantly prolong life. While much clinical effort is expended on treating sequential life-threatening infections, the overall course is usually progressively downhill. Thus, any real impact on the disease should be aimed at the causative viral agent, because it is destruction of a critical component of the immune system that predisposes to opportunistic infections.
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000382:microbiology; D000328:Adult; D002177:Candidiasis / Q000209:etiology; D003453:Cryptococcosis / Q000209:etiology; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000209:etiology; D008297:Male; D009164:Mycobacterium Infections / Q000209:etiology; D009181:Mycoses / Q000209:etiology; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000209:etiology; D065227:Transfusion Reaction; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014777:Virus Diseases / Q000209:etiology
chemical_list: D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole